GlassScriptPhysician profile
Matthew Tanner Crabtree
NPI 1861951675
$1,708.17
in general payments reported to CMS, 2019-2025
22 companies · $900 in 2025
The $900 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.42 · 2024: $794 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.48 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $325.84 | 2024-2025 | Tepezza, Repatha, Otezla |
| Ucb, INC. | $309.73 | 2024-2025 | Bimzelx, Cimzia |
| Novo Nordisk INC | $259.11 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Radius Health, INC. | $99.15 | 2024-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $94.30 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $77.01 | 2024-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $58.52 | 2024 | Ilet Bionic Pancreas |
| Novartis Pharmaceuticals Corporation | $55.63 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $49.36 | 2025 | Yorvipath |
| Abbvie INC. | $48.64 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $46.75 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.12 | 2024 | Ofev |
| Lilly USA, LLC | $43.08 | 2024-2025 | Jardiance |
| Ascensia Diabetes Care US INC. | $40.32 | 2024-2025 | |
| Ardelyx, INC. | $30.00 | 2025 | Ibsrela |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $21.91 | 2024 | |
| Madrigal Pharmaceuticals | $21.56 | 2024 | Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $18.08 | 2025 | |
| Fresenius Kabi USA, LLC | $16.78 | 2025 | |
| Scilex Pharmaceuticals INC. | $16.34 | 2024 | |
| Daiichi Sankyo INC. | $15.52 | 2025 | Injectafer |
| Grt US Holding, INC. | $14.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Crabtree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.